公开(公告)号：US20090130228A1

公开(公告)日：2009-05-21

申请号：US12280629

申请日：2007-02-28

申请人： Silvio Ernesto Perea Rodriguez ,  Yasser Perera Negrin ,  Arielis Rodriguez Ulloa ,  Jeovanis Gil Valdes ,  Yassel Ramos Gomez ,  Lila Rosa Castellanos Serra ,  Lazaro Hiram Betancourt Nunez ,  Aniel Sanchez Puente ,  Jorge Fernandez de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier Gonzalez Lopez ,  Vladimir Besada Perez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

发明人： Silvio Ernesto Perea Rodriguez ,  Yasser Perera Negrin ,  Arielis Rodriguez Ulloa ,  Jeovanis Gil Valdes ,  Yassel Ramos Gomez ,  Lila Rosa Castellanos Serra ,  Lazaro Hiram Betancourt Nunez ,  Aniel Sanchez Puente ,  Jorge Fernandez de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier Gonzalez Lopez ,  Vladimir Besada Perez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

IPC分类号： A61K33/24 ,  A61K38/08 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/704 ,  A61K31/675 ,  A61K31/407 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/7088 ,  A61P35/00

CPC分类号： A61K38/08 ,  A61K31/136 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，mitomicin C，伊马替尼，iressa和velcade（vortezomib）。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。